Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
Amantadine (1) ·
Apomorphine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Bromocriptine (1) ·
Buprenorphine (1) ·
Butorphanol (1) ·
Cabergoline (1) ·
Carbidopa/levodopa (1) ·
Codeine (2) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Entacapone (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Levodopa (1) ·
Levorphanol (1) ·
Meperidine (1) ·
Methadone (1) ·
Nalbuphine (1) ·
Opicapone (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Rasagiline (1) ·
Rotigotine (1) ·
Safinamide (1) ·
Selegiline (1) ·
Tapentadol (1) ·
Tolcapone (1) ·
Trihexyphenidyl (1)
brand:
None (6) ·
(multiple, generic dominant) (1) ·
Akineton (1) ·
Apokyn (1) ·
Artane (1) ·
Azilect (1) ·
Cogentin (1) ·
Comtan (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Dolophine (1) ·
Dostinex (1) ·
Duragesic (1) ·
Eldepryl (1) ·
Neupro (1) ·
Nubain (1) ·
Nucynta (1) ·
Ongentys (1) ·
Opana (1) ·
Parlodel (1) ·
Rexulti (1) ·
Sinemet (1) ·
Stadol (1) ·
Suboxone (1) ·
Symmetrel (1) ·
Talwin (1) ·
Tasmar (1) ·
Vicodin (1) ·
Xadago (1)
classes: (Click arrow to add another value)
mechanism:
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Peripheral COMT inhibitor (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Selective M1 muscarinic antagonist (1)
uses:
None (33) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
preparations:
fda max:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 35 results in range #1 to #35.